Literature DB >> 15507981

First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).

Lorraine Dugoff1, John C Hobbins, Fergal D Malone, T Flint Porter, David Luthy, Christine H Comstock, Gary Hankins, Richard L Berkowitz, Irwin Merkatz, Sabrina D Craigo, Ilan E Timor-Tritsch, Steven R Carr, Honor M Wolfe, John Vidaver, Mary E D'Alton.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether maternal serum levels of pregnancy-associated plasma protein A, free-beta subunit human chorionic gonadotropin, or nuchal translucency size are associated with obstetric complications. STUDY
DESIGN: Data were obtained from the First and Second Trimester Evaluation of Risk trial. Pregnancy-associated plasma protein A and free-beta subunit human chorionic gonadotropin levels were analyzed, and nuchal translucency was measured between 10 weeks 3 days and 13 weeks 6 days of gestation in 34,271 pregnancies.
RESULTS: Women with pregnancy-associated plasma protein A of < or =5th percentile were significantly more likely to experience spontaneous fetal loss at < or =24 weeks of gestation, low birth weight, preeclampsia, gestational hypertension, preterm birth ( P < .001) and stillbirth, preterm premature rupture of membranes, and placental abruption ( P < .02). Nuchal translucency at > or =99th percentile and free-beta subunit human chorionic gonadotropin at < or =1st percentile were associated with an increased risk of spontaneous loss at < or =24 weeks of gestation (adjusted odds ratios, 3.90, 3.62, respectively; P < .001).
CONCLUSION: Low pregnancy-associated plasma protein A levels in the first trimester were associated strongly with a number of adverse pregnancy outcomes. Low free-beta subunit human chorionic gonadotropin levels and large nuchal translucency were both associated with early fetal loss.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507981     DOI: 10.1016/j.ajog.2004.06.052

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  75 in total

1.  Management of abnormal serum markers in the absence of aneuploidy or neural tube defects.

Authors:  William T Schnettler; Michele R Hacker; Rachel E Barber; Sarosh Rana
Journal:  J Matern Fetal Neonatal Med       Date:  2012-03-26

2.  A test of maternal human chorionic gonadotropin during pregnancy as an adaptive filter of human gestations.

Authors:  Tim A Bruckner; Katherine B Saxton; Michelle Pearl; Robert Currier; Martin Kharrazi
Journal:  Proc Biol Sci       Date:  2012-09-26       Impact factor: 5.349

3.  First-trimester combined screening is effective for the detection of unbalanced chromosomal translocations at 11 to 12 weeks of gestation.

Authors:  Shangyu Huang; Chialin Chang; Pojen Cheng; Chinghua Hsiao; Yungkuei Soong; Tao Duan
Journal:  Reprod Sci       Date:  2013-10-31       Impact factor: 3.060

4.  Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.

Authors:  Mithil Patil; T M Panchanadikar; Girija Wagh
Journal:  J Obstet Gynaecol India       Date:  2013-12-01

5.  Association of early-preterm birth with abnormal levels of routinely collected first- and second-trimester biomarkers.

Authors:  Laura L Jelliffe-Pawlowski; Gary M Shaw; Robert J Currier; David K Stevenson; Rebecca J Baer; Hugh M O'Brodovich; Jeffrey B Gould
Journal:  Am J Obstet Gynecol       Date:  2013-02-24       Impact factor: 8.661

6.  Fetal membrane transport enhancement using ultrasound for drug delivery and noninvasive detection.

Authors:  Lior Wolloch; Aharon Azagury; Riki Goldbart; Tamar Traitel; Gabriel Groisman; Mordechai Hallak; Joseph Kost
Journal:  Pharm Res       Date:  2014-07-31       Impact factor: 4.200

7.  The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.

Authors:  Liona C Poon; Andrew Shennan; Jonathan A Hyett; Anil Kapur; Eran Hadar; Hema Divakar; Fionnuala McAuliffe; Fabricio da Silva Costa; Peter von Dadelszen; Harold David McIntyre; Anne B Kihara; Gian Carlo Di Renzo; Roberto Romero; Mary D'Alton; Vincenzo Berghella; Kypros H Nicolaides; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2019-05       Impact factor: 3.561

8.  First-trimester prediction of preterm birth using ADAM12, PAPP-A, uterine artery Doppler, and maternal characteristics.

Authors:  Katherine R Goetzinger; Alison G Cahill; Janet Kemna; Linda Odibo; George A Macones; Anthony O Odibo
Journal:  Prenat Diagn       Date:  2012-07-31       Impact factor: 3.050

Review 9.  Potential markers of preeclampsia--a review.

Authors:  Simon Grill; Corinne Rusterholz; Rosanna Zanetti-Dällenbach; Sevgi Tercanli; Wolfgang Holzgreve; Sinuhe Hahn; Olav Lapaire
Journal:  Reprod Biol Endocrinol       Date:  2009-07-14       Impact factor: 5.211

10.  Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study.

Authors:  Samantha J Lain; Charles S Algert; Vitomir Tasevski; Jonathan M Morris; Christine L Roberts
Journal:  BMC Med Res Methodol       Date:  2009-07-09       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.